AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$AXON

Kunins Jeffrey C sold $6.0M of AXON

Kunins Jeffrey C (CPO & CTO) sold 9,605 shares of AXON ENTERPRISE, INC. (AXON) at an average of $626.70 ($605.77–$635.02, $6.02M total) across 24 trades on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kunins Jeffrey C
Published Aug 24, 2026, 9:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AXON
Bearish
medium confidence
Mentioned
$AXON
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXONBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a lack of confidence, but the pre‑arranged plan tempers the signal.

02

Market read

First‑time disclosure of a $6M insider sale; modest short‑term impact expected.

03

What to watch

The 10b5‑1 plan suggests the sale was pre‑planned, reducing the informational value of the transaction.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑08‑21

Background

Form 4 filings disclose insider transactions; a CPO/CTO sale is noteworthy for investors.

Company-level read

Ticker impact

$AXONBearishMedium confidence
Context

Officer sold 9,605 shares for $6.0M via a 10b5-1 plan, reducing his stake to 97,761 shares.

Expected impact

Modest downside pressure over the next few days.

Evidence & confidence

A $6M sale by the CPO/CTO is material for a mid‑cap company and is disclosed for the first time.

Market effects

Sector

Minimal; insider activity does not materially affect the broader medical‑device sector.

Regional

Limited to U.S. investors tracking Axon Enterprise.

Global

Low; no cross‑border implications.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event under a pre‑arranged plan, not a bearish signal.

Key entities

  • Officer
    Kunins Jeffrey C

    Chief Product Officer & Chief Technology Officer of Axon Enterprise.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AXON insider trading history →

Related articles

AUG 23
$AXONMedAI 8/10

Axon’s AI Era Revenue Jumped Nearly 700%. Here’s What’s Behind It

Axon Enterprise (AXON) reported 35% revenue growth to $904M, beating estimates. AI Era revenue surged nearly 700% YoY. Management raised full-year guidance to 32-34% growth. Gross margin slipped 40 basis points to 62.9%. Analysts estimate a target price of $714, implying 13.7% upside over 2.4 years. The stock trades at 70x forward earnings, with growth driven by software and AI products.

tikr.com3 min
AUG 20
$BABAHighAI 8/10

Breakfast News: Alibaba's AI Push Comes at a Cost

Alibaba's Q1 revenue rose 9% to $39.6B, but operating income fell 57% due to tech investments. BILL Holdings reported 14% revenue growth and 80% operating income increase. U.S. debt surpassed $40T, with Treasury buybacks easing yield pressure. Apple plans 2027 launch for camera AirPods. Axon Enterprise passes competitive position tests, with a 69% potential upside to $1,088.08.

fool.com4 min
AUG 10
$AXONMed

Axon Stock Rebounds As Its Margin Squeeze Looks Like The Price Of Growth

Axon Enterprise (AXON) shares rose 9.3% on Friday after a 14.3% drop the prior session following its Q2 2026 results. The quarter showed revenue of $904 million, up 35% year over year, and a raised full-year outlook. The market disagreed over margin compression tied to higher memory costs and counter-drone hardware mix, with Axon expecting Q3 adjusted EBITDA margin to hold and rebuild in Q4.

finance.yahoo.com4 min
AUG 7
$AXONMed

Raise. So Why Is the Stock Down?

Axon Enterprise (NASDAQ: AXON) reported Q2 revenue of $904M, up 35% year over year, beating estimates of $876.5M. Adjusted EBITDA rose 40% to $242M, and adjusted EPS was $1.88 vs $1.84 expected. Axon raised full-year revenue guidance to 32%-34% growth but reduced software and services gross margin and withdrew operating cash flow and free cash flow guidance.

aol.com4 min